We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Eco Animal Health Group Plc | EAH | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 71.00 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 71.00 | 71.00 | 71.00 | 71.00 | 71.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Announcement Date | Type | Currency | Dividend Amount | Ex Date | Record Date | Payment Date |
|---|---|---|---|---|---|---|
| Final | GBP | 0.01 | 23/09/2021 | 24/09/2021 | 22/10/2021 |
| Top Posts |
|---|
Posted at 02/12/2024 13:10 by cerrito From CitywireNote that in August Shore retained their Fair Value target share price at 175p so seem to have downgraded their opinion since then, quote Vet pharmaceutical group Eco Animal Health (EAH) is still trading at a ‘sizeable̵ Analyst Sean Conroy retained his ‘buy’ recommendation and ‘fair value’ target price of 140p on the stock, which climbed 11.7% to 71.3p last week despite a 13% decline in half-year revenues due to weaker sales in China and Japan. Conroy said the group is trading on an enterprise value/[pre-tax profits] of 4.7 times full-year 2025, which is ‘still a sizeable discount to animal health peers’. Our discounted cashflow, which encapsulates the growth potential of the pipeline, suggests fair value of 165p and implies Eco Animal Health should trade closer to the peer average,’ he said. ‘Securing regulatory approval for its first poultry vaccine should cement upside. Discounting the pipeline dynamics from our model, we see fair value at 140p.’ Conroy added that pipeline development remains fully self-funded and ‘2025 will represent a pivotal period as Eco Animal Healy looks to secure approvals’. |
Posted at 28/11/2024 07:50 by edmonda "FY25 interims point to a stronger second half"For the six months to 30 September 2024 ECO Animal Health reported revenue of £33.2m, -13%YoY and (adj.) EBITDA of £0.45m (H1 23: £0.7m). The gross margin remained firm at 40.3% compared to 40.8% a year earlier. In the October Trading Update (Equity Development report ‘Trading update: headwinds in China’) the Group reported that the combination of a lower incidence of disease and reduced Aivlosin® demand in China and SE Asia markets meant that FY25 (adj.) EBITDA would be c.£7.2m. Into H2 the Group has seen “demand accelerate” to the extent that 82% of market consensus revenue is now covered by year-to-date revenue combined with orders and run rate across operations worldwide. Consequently, the (adj.) EBITDA outlook is reiterated. Following the Trading Update, and in light of Interim results, our Fair Value range is revised to 97p – 102p based on an updated comparative review of EAH peers. We note that this valuation includes only the initial (R&D etc.) costs but not the full potential contribution from next-generation products under development. Link to note: |
Posted at 25/11/2024 16:50 by sharesoc We will be hosting a SIGnet follow-up meeting on December 12 at 7:00 pm to discuss and analyse the latest developments at Eko Animal Health (EAH), following their interim results presentation with Investor Meet Company on December 4.Register now: |
Posted at 11/10/2024 09:49 by boonkoh There's a good investor presentation on YouTube. Search EAH Proactive One2One.Minute 10 onwards reveals that the company thinks peak EBITDA from the vaccines could be £160m/yr. Current EBITDA is £7-8m/yr.Estimated NPV of the portfolio is £84m (vs current market cap of £48m).But the average time range to hit peak revenues is probably 2032-2035....(I hold in the Boon Fund) |
Posted at 07/10/2024 22:49 by cerrito At the time of Truss when £ was very weak I remember wondering if they would be taken over by a company with a well established sales force in many countries and while of course the £ is now much stronger the weak share price makes me ask the same question again.As far as I can see very little trading today and while that of the middle of last week was v active be EAH standards not enough to suggest dumping by a major II. Too bad it is not the case of holders locking in their capital gains before the budget. |
Posted at 01/10/2024 07:12 by boonkoh Broker forecast cuts now in. Equity Dev and Singer -10% and -13% ebitda for FY25. Moderate mild cuts.Singer maintains price target of 258p (!!) saying value in EAH is the upcoming new product launches in 2025-2026. Let's see if the market agrees...(I hold in the Boon Fund) |
Posted at 01/10/2024 06:23 by waldron Eco Animal Health Group PLC Trading Update01/10/2024 7:00am RNS Regulatory News RNS Number : 3399G Eco Animal Health Group PLC 01 October 2024 1 October 2024 ECO Animal Health Group plc ("ECO" or the "Company") Trading Update ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, today announces an update on its trading for the six months ending 30 September 2024. Aivlosin® continues to gain market share in key territories, particularly Brazil and India, with revenues in these regions exceeding the Board's expectations. In addition, and as expected, we are continuing to gain market share in the US. We are however, encountering challenges in China, due to low disease incidence in the summer months, and in Southeast Asia, where sales have slowed reflecting some customer churn. The ECO Group is second half weighted and this pattern will continue in FY 2025. Nevertheless, the recent challenges we've faced in China and Southeast Asia lead us to believe that revenue for the full year will be materially below market expectations.1 Due to the complex mix of geographies in which the ECO Group operates, foreign exchange headwinds, and the differing gross margins across each region, forecasting an adjusted EBITDA figure for the full year at this stage is challenging. The Board expects that adjusted EBITDA for FY25 will be in the region of that observed in FY23 and notes it is likely that more accurate guidance will be provided when interim results to 30 September 2024 are announced in late November.2 The ECO Group has grounds for optimism for an improved performance in the second half with pork prices improving in China, strong order books and continuing strength in North America, Brazil and India. In addition, we have recently been notified that the ECO Group has received regulatory approval for the marketing of Aivlosin® in Paraguay. This market produced 1.4m pigs in 2023, nearly 80% of which were in industrial farms. The ECO Group is strongly cash generative and has a non-China cash balance in-line with that on hand at 31 March 2024. This ensures that the ECO Group's valuable R&D programme continues to move forward on a self-funded basis at the planned rate. 1. The Board understands market expectations for revenue and EBITDA in FY25 is £92.6m and £8.2m respectively. 2. Reported audited revenue and adj EBITDA for FY23 was £85.3m and £7.2m respectively. -Ends- |
Posted at 30/8/2024 09:14 by cerrito saw this.Those of you who were more on the ball than me and who bought a couple of weeks back in the mid 90's will not regret it. quote Vet pharmaceutical group Eco Animal Health (EAH) could be through its nadir and on the cusp of an attractive period of growth, says Shore Capital. Analyst Sean Conroy retained his ‘buy’ recommendation and a ‘fair value’ target price of 175p on the stock, which softened 0.8% to 106.7p on Tuesday, putting it down 2.1% over the last year. Full-year 2024 results from the group ‘evidenced a robust performance from Aivlosin (used in drinking water for turkeys and chickens), which underpinned the delivery of +11% top-line growth despite the recent, challenging period its customers have faced’. unquote ‘We sense the sentiment nadir could be passing with respect to the current lull in the hog cycle and highlight that Eco Animal Health should benefit if pork producers continue to return to profitability,’ The next 18 months will ‘represent a pivotal period’ as the company looks to secure regulatory approvals and launch new products, and ‘looks set to offer an attractive period of near-term growth’. |
Posted at 16/8/2024 06:15 by grupo guitarlumber ECO Animal Health Group plc("ECO" or the "Company") Posting of the Annual Report and Notice of AGM ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that its Annual Report and Accounts for the year ended 31 March 2024 and Notice of Annual General Meeting ("AGM") together with Form of Proxy have today been sent to shareholders who have elected to receive hard copies by post. The Annual Report and Accounts is available on the Company's website at The Company will hold its AGM at The Grange, 100 High Street, London, N14 6BN on Thursday, 26 September 2024 at 9:00 am. A copy of the Notice of AGM and Form of Proxy will be available on the Company's website at -Ends- |
Posted at 15/7/2024 06:21 by edmonda ECO Animal Health (LON:EAH) - "Strong FY24 results: 11% underlying growth", new note available here: For the year ended 31st March 2024, ECO Animal Health Group reported revenue +5%YoY at £89.4m, which on a currency-adjusted basis was +11%YoY, and (adj.) EBITDA of £8.0m, +11.2%YoY which was ahead of market consensus on an improvement in margin from 8.5% to 9.0%. The impact of currency volatility was evident in gross profitability at 42.1% compared to 45.0% a year earlier; H2 recovered to 43.1%. (Adj.) EBIT was 14%YoY lower at £4.6m, a 5.1% margin compared to 6.3% in FY23. Having rallied 30%YoY, EAH shares are trading 7% off its recent year high. We have derived a Fair Value per share range of 137p-146p based on the initial, medium-term, valuation of the pipeline of products under development. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
